Literature DB >> 6166700

Expression of hybrid Ia molecules on the cell surface of reticulum cell sarcomas that are undetectable on host SJL/J lymphocytes.

S M Wilbur, B Bonavida.   

Abstract

SJL/J (H-2 (8)) lymphocytes, primed in vitro against primary, cultured, and transplantable syngeneic reticulum cell sarcomas (RCS) were found to recognize and bind to the tumor without subsequent cytolysis. Additional data showed that the recognition was also directed against Ia molecules of the H-2(d), but not H-2(k), haplotype. Normal spleen cells of DBA/2, B 10.D2, and B 10.OL mice were bound, whereas those of CBA, B 10.BR, B 10.A, B 10.GD, and D2.GD were not. Furthermore, the Ia molecules were in the form of a hybrid, because spleen cells from F(1) progeny of a B10.A and a B10.GD parent were recognized and bound as effectively as the RCS. Recognition was not restricted solely to the H-2(d) haplotype. Spleen cells from B10.S(9R) mice were also significantly bound. This result suggested that the RCS expresses a hybrid Ia molecule containing a beta-chain of the H-2(8) haplotype. Recognition of this hybrid Ia molecule by the host resulted in a cross- reactive recognition of H-2(d) specificities. Further analysis revealed that the RCS express on their cell surface an alpha-chain of the hybrid Ia molecule which is involved in host anti-tumor recognition. Preincubation of the RCS with monoclonal antibody directed against the Ia.7 specificity on the alpha-chain could block lymphocyte-to-tumor cell binding. The blocking activity could be removed by preabsorption of the antibody on the RCS, as well as normal Ia.7-bearing lymphocytes, but not on lymphocytes that do not express Ia.7, such as SJL/J. The data suggest that the hybrid Ia molecules expressed on the RCS, and recognized by tumor-primed syngeneic lymphocytes, are composed of both a syngeneic and an alien chain. The component alien to the SJL/J host is the Ia.7-bearing alpha-chain. Normal SJL/J cells synthesize but do not express the beta-chain. In the RCS, however, alien alpha-chain synthesis permits expression of the syngeneic beta-chain in the form of a hybrid Ia molecule.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166700      PMCID: PMC2186102          DOI: 10.1084/jem.153.3.501

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  Polymorphism and linkage of glutathione reductase in Mus musculus.

Authors:  E A Nichols; F H Ruddle
Journal:  Biochem Genet       Date:  1975-06       Impact factor: 1.890

2.  Complementation of H-2-linked Ir genes in the mouse.

Authors:  M E Dorf; B Benacerraf
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

3.  B-cell alloantigens determined by the H-2 linked Ir region are associated with mixed lymphocyte culture stimulation.

Authors:  E C Lozner; D H Sachs; G M Shearer; W D Terry
Journal:  Science       Date:  1974-02-22       Impact factor: 47.728

Review 4.  Structural and serological properties of murine Ia alloantigens.

Authors:  S E Cullen; J H Freed; S G Nathenson
Journal:  Transplant Rev       Date:  1976

5.  Early steps in specific tumor cell lysis by sensitized mouse T lymphocytes. I. Resolution and characterization.

Authors:  E Martz
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

6.  Properties of reticulum-cell sarcomas in SJL/J mice. I. Proliferative response to tumor cells of T-derived lymphoid cells from normal mice.

Authors:  S P Lerman; J M Chapman; E A Carswell; G J Thorbecke
Journal:  Int J Cancer       Date:  1974-12-15       Impact factor: 7.396

7.  The requirement for two complementing Ir-GLphi immune response genes in the T-lymphocyte proliferative response to poly-(Glu53Lys36Phe11).

Authors:  R H Schwartz; M E Dorf; B Benacerraf; W E Paul
Journal:  J Exp Med       Date:  1976-04-01       Impact factor: 14.307

8.  Functional subclasses of T-lymphocytes bearing different Ly antigens. I. The generation of functionally distinct T-cell subclasses is a differentiative process independent of antigen.

Authors:  H Cantor; E A Boyse
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

9.  Macrophage-lymphocyte interaction. II. Antigen-mediated physical interactions between immune guinea pig lymph node lymphocytes and syngeneic macrophages.

Authors:  P E Lipsky; A S Rosenthal
Journal:  J Exp Med       Date:  1975-01-01       Impact factor: 14.307

10.  Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells.

Authors:  H Shiku; P Kisielow; M A Bean; T Takahashi; E A Boyse; H F Oettgen; L J Old
Journal:  J Exp Med       Date:  1975-01-01       Impact factor: 14.307

View more
  5 in total

1.  Intimate host-tumor interaction in the spontaneous reticulum cell sarcoma of SJL/J mice: is it an exceptional case?

Authors:  B Bonavida
Journal:  Surv Immunol Res       Date:  1985

2.  Properties of reticulum cell sarcomas in SJL/J mice. VIII. Prominent role of RCS cell I-A antigens in the stimulation of syngeneic T cells.

Authors:  P H Brown; D Mathis; R E Cone; P P Jones; N M Ponzio; G J Thorbecke
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

3.  Experimental models of lymphoproliferative disease. The mouse as a model for human non-Hodgkin's lymphomas and related leukemias.

Authors:  P K Pattengale; C R Taylor
Journal:  Am J Pathol       Date:  1983-11       Impact factor: 4.307

4.  Induced type-B reticulum cell neoplasia of CBA mice. II. Functional similarities between tumorigenic reticulum cells and normal accessory cells.

Authors:  M P Brittle; M C Jacob; K J Gomer
Journal:  Immunology       Date:  1985-08       Impact factor: 7.397

5.  The SJL/J T cell response to both spontaneous and transplantable syngeneic reticulum cell sarcoma is mediated predominantly by the V beta 17a+ T cell clonotype.

Authors:  J D Katz; K Ohnishi; L T Lebow; B Bonavida
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.